Gateways to clinical trials: September 2004

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 26, Issue 7, 2004, Pages 587-612

  Bayes M ^a   Rabasseda, X ^b   Prous, J R ^b  

^a PROUS SCIENCE   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

101 M; ABETIMUS; ADEFOVIR DIPIVOXIL; ALEFACEPT; AMD 070; AMPHOTERICIN B; AMPRENAVIR PHOSPHATE; AP 12009; AP 23573; APC 8024; ARIPIPRAZOLE; ATL 962; ATOMOXETINE; BEVACIZUMAB; BIMATOPROST; BORTEZOMIB; BOSENTAN; BR 1; CALCIPOTRIOL; CELECOXIB; CRM 197; DESLORATADINE; EFALIZUMAB; ELCOMETRINE; ELETRIPTAN; ENFUVIRTIDE; ENTECAVIR; EP 2101; EPLERENONE; ERLOTINIB; ETORICOXIB; EVEROLIMUS; FROVATRIPTAN; HSPPC 96; IMATINIB; INFLUENZA VACCINE; INSULIN GLARGINE; IRX 2; L 759274; LEVODOPA; LY 156735; PCK 3145; RECOMBINANT INTERLEUKIN 12; RG 228; S 3304; SDZ SID 791; SGN 30; TH 9507; UNINDEXED DRUG;

ACUTE HEART INFARCTION; BONE DISEASE; CANCER; CARDIOVASCULAR DISEASE; CLINICAL STUDY; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; CONGESTIVE CARDIOMYOPATHY; CONNECTIVE TISSUE DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ENDOCRINE DISEASE; EYE DISEASE; HEART FAILURE; HEPATITIS B; HEPATITIS C; HEPATOBILIARY DISEASE; HUMAN; HYPERTENSION; IMMUNOPATHOLOGY; LIVER INJURY; MEDICAL LITERATURE; MENTAL DISEASE; META ANALYSIS; METABOLIC DISORDER; METHODOLOGY; MUSCULOSKELETAL DISEASE; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUROTOXICITY; NUTRITIONAL DISORDER; PRACTICE GUIDELINE; RESPIRATORY TRACT DISEASE; REVIEW; SKIN DISEASE; SKIN MANIFESTATION; SYSTEMATIC REVIEW; URINARY TRACT DISEASE;

CARDIOVASCULAR DISEASES; COMMUNICABLE DISEASES; DOUBLE-BLIND METHOD; HUMANS; LIVER DISEASES; METABOLIC DISEASES; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS;

EID: 8344283568     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (158)

1. Benza, R.L., Rayburn, B.K., Tallaj, J.A. et al. The safety and efficacy of bosentan in pulmonary hypertension due to congenital heart disease. J Heart Lung Transplant 2003, 22 (Suppl. 1): Abst 242.
2. Menard, J., Bittman, R., Gatlin, M. Eplerenone dose-response relationship for aldosterone blockade. Am J Hypertens 2003, 16 (5, Part 2): Abst P-354.
3. Ram, C.V.S., Silfani, T. A comparative analysis of the efficacy of olmesartan medoxomil (O)/hydrochlorothiazide (HCTZ), valsartan (V)/HCTZ, irbesartan (I)/HCTZ and telmisartan/HCTZ combinations. Am J Hypertens 2004, 17 (5, Part 2): Abst P-243.
4. Cheng, D.C.H., Mazer, C.D., Martineau, R. et al. A phase II dose-response study of hemoglobin raffimer (Hemolink) in elective coronary artery bypass surgery. J Thorac Cardiovasc Surg 2004, 127(1): 79.
5. Danaher, PJ. et al. Reversible dilated cardiomyopathy related to amphotericin B therapy. J Antimicrob Chemother 2004, 53(1): 115.
6. Zannad, F., Pitt, B. EPHESUS: Evidence for the cardioprotective effects of selective aldosterone blockade. J Hypertens 2004, 22 (Suppl. 2): Abst 8A.1.
7. Truong, K.M., Bernabei, A.F., Czerska, B. Nesiritide use in end stage heart failure. J Heart Lung Transplant 2003, 22 (Suppl. 1): Abst 113.
8. Ohashi, N., Uematsu, T., Nagashima, S. et al. The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis. Br J Clin Pharmacol 2004, 57(6): 726.
9. Jacoby, K., Mack, R., Nevins, G., Rodzvilla, J., Smith, T. Evaluation of the long-term safety profile of a new testosterone gel (Testim®). 86th Annu Meet Endocr Soc (June 16, 2004, New Orleans) 2004: Abst P2-555.
10. Farkas, H. et al. The efficacy and tolerability of desloratadine in seasonal allergic rhinitis. World Allergy Organ Congr (Sept 7, 2003, Vancouver) 2003: Abst P-16-42.
11. Campochiaro, PA. Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest Ophthalmol Visual Sci 2004, 45(3): 922.
12. Cardascia, N., Sisto, D., Trabucco, T. et al. Water-drinking test in patients affected by primary open-angle glaucoma under several types of topical medications. 5th Int Symp Ocular Pharmacol Ther (March 11, 2004, Monte Carlo) 2004.
13. Elias, E., Mills, C., Halphen, M., Barras, N., Gruss, H.-J. et al. Cholyl-lysyl-fluorescein (CLF) clearance provides a reproducible dynamic liver function test. Dig Dis Week (May 17, 2003, Orlando) 2003: Abst M1436.
14. Conchillo, M. et al. Results of a randomized double-blind, controlled pilot study of the administration of insulin-like growth factor-1 (IGF-1) in patients with liver cirrhosis. J Hepatol 2004, 40 (Suppl. 1): Abst 180.
15. Shiffman, M. et al. HBsAg seroconversion in adefovir dipivoxil (ADV) treated chronic hepatitis B (CHB) patients. J Hepatol 2004, 40 (Suppl. 1): Abst 45.
16. Vigano, M., et al. Rescue treatment with adefovir dipivoxil in lamivudine resistant patients with chronic hepatitis B. J Hepatol 2004, 40 (Suppl. 1): Abst 448.
17. Colombatto, P. et al. A new bio-mathematical model to describe the dynamics of HBV-DNA and infected hepatocytes in HBeAg-negative/anti-Hbe-positive chronic hepatitis B patients treated with peginterferon alfa-2a (40KD) (Pegasys®), lamivudine, or Pegasys® plus lamivudine combination. J Hepatol 2004, 40 (Suppl. 1): Abst 421.
18. Perrillo, R. et al. Continued safety and efficacy of adding adefovir dipivoxil (ADV) to ongoing lamivudine (LAM) therapy in compensated chronic hepatitis B (CHB) patients with YMDD variant HBV: 2 year results. J Hepatol 2004. 40 (Suppl. 1): Abst 438.
19. Romero-Gomez, M. et al. Insulin resistance, fibrosis and genotype are predictors of sustained response rate to pegylated interferon plus ribavirin in patients with chronic hepatitis C. J Hepatol 2004, 40(Suppl. 1): Abst 508.
20. Piccolo, P. et al. Peginterferon alpha-2a (40KD) monotherapy vs peginterferon alpha-2a and ribavirin in naïve patients with chronic hepatitis C: Preliminary results of the SMIEC II trial in patients with early viral clearance on peginterferon monotherapy. J Hepatol 2004, 40 (Suppl. 1): Abst 502.
21. Castera, L. et al. Psychiatric events during peginterferon and ribavirin therapy in chronic hepatitis C (CHC): Results of a prospective study in 98 patients. J Hepatol 2004, 40 (Suppl. 1): Abst 470.
22. Jeffers, L.J. et al. Peginterferon alpha-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004, 39(6): 1702.
23. Reddy, K.R. et al. The influence of cumulative exposure to combination peginterferon alfa-2a (40 KD) (Pegasys) and ribavirin on sustained virological response (SVR) rates in patients with genotype 1 chronic hepatitis C. J Hepatol 2004, 40 (Suppl. 1): Abst 505.
24. Sanchez-Tapias, J.M. et al. Sustained virological response after prolonged treatment with peginterferon alfa-2a (40KD) (Pegasys®) and ribavirin (Copegus®) in treatment-naïve patients with chronic hepatitis C and detectable HCV RNA after week4 of therapy: TeraViC-4 study. J Hepatol 2004, 40 (Suppl. 1); Abst 509.
25. Buti, M., Valdes, A., Mendez, C. et al. HCV core Ag as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon alfa-2b plus ribavirin. J Hepatol 2004, 40 (Suppl. 1): Abst 466.
26. Zeuzem, S. et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004, 40(6): 993.
27. Muir, A.J. et al. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. New Engl J Med 2004, 350(22): 2265.
28. Lorenzini, S., Biselli, M., Gramenzi, A. et al. Pegylated interferon plus ribavirin for the treatment of recurrent HCV infection after liver transplantation. J Hepatol 2004, 40 (Suppl. 1): Abst 489.
29. Gonzalez, V. et al. Total HCV core antigen correlates with HCV RNA, and predicts sustained virological response (SVR) to peginterferon alfa 2-a (PEG-IFN) and ribavirin (RIB) therapy in chronic hepatitis C (CHC). J Hepatol 2004, 40 (Suppl. 1): Abst 480.
30. Stuebner, U.R. Horak, R. Zieglmeyer, R. et al. Desloratadine reduces nasal congestion and other signs and symptoms of allergic rhinitis (AR) induced by house dust mite (HDM) allergen exposure in the Vienna challenge chamber. J Allergy Clin Immunol 2003, 111 (2, Part 2): Abst 42.
31. Chang, E.E., El-Dahr, J.M. The effect of pimecrolimus on prick skin testing. J Allergy Clin Immunol 2003, 111 (2, Part 2): Abst 350.
32. Hirschman, S.Z., Shtemer, Z., Didiego, M., D'Olimpio, J.T. Anti-cachectic effects of a novel peptide nucleic acid: Preliminary results of a phase I/II clinical trial. Proc Am Soc Clin Oncol 2004, 23: Abst 8087.
33. Schiff, E.R., Chang, T.T., Gish, R.G., et al. Entecavir 10 mg is consistently superior to lamivudine at 48 weeks across multiple baseline HBV disease characteristics in lamivudine-refractory patients. J Hepatol 2004, 40 (Suppl. 1): Abst 442.
34. Gish, R.G., Chang, T.T., Hadziyannis, S. et al. Lamivudine-refractory hepatitis B patients can be safely switched directly to entecavir 1 mg daily therapy. J Hepatol 2004, 40 (Suppl. 1): Abst 428.
35. Weiland, O. et al. Combination therapy with peginterferon alfa-2a (40KD) (Pegasys®) plus ribavirin (Copegus®) in treatment-naive patients with chronic hepatitis C and genotype 1 infection: Individual estimated probability of sustained virological response (SVR). J Hepatol 2004. 40 (Suppl. 1): Abst 522.
36. Maggi, P. et al. Cutaneous injection site reactions to long-term therapy with enfuvirtide. J Antimicrob Chemother 2004, 53(4): 678.
37. Rodriguez-French, A., Boghossian, J., Gray, G.E. et al. The NEAT study: A 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J Acquir Immune Defic Syndr (JAIDS) 2004, 35(1): 22.
38. Husain, S. et al. Role of voriconazole prophylaxis for the prevention of invasive aspergillosis (IA) at six months in lung transplant recipients. J Heart Lung Transplant 2004, 23 (2, Suppl. 1): Abst 205.
39. Gaglani, M.J., Piedra, P.A., Herschler, G.B. et al. Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children. Arch Pediatr Adolesc Med 2004, 158(1): 65.
40. Villahermosa, L.G. et al. Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy. Am J Trop Med Hyg 2004, 70(2): 197.
41. Rosenstock, J., Cappelleri, J.C., Bounder, B., Gerber, R.A. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) patients with type 1 or type 2 diabetes. Diabetes Care 2004, 27(6): 1318.
42. Kidron, M., Dinh, S., Menachem, Y. et al. A novel per-oral insulin formulation: Proof of concept study in non-diabetic subjects. Diabet Med 2004, 21(4): 354.
43. Heise, T. et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004, 53(6): 1614.
44. Frost, CE. et al. Lipid lowering effects of multiple dose administration of muraglitazar (BMS-298585), a novel PPARα/γ dual agonist, in type 2 diabetic patients. 64th Annu Meet Sci Sess Am Diabetes Assoc (June 4, 2004, Orlando) 2004: Abst 1988-PO.
45. Mosqueda-Garcia, R. et al. Glucose lowering effects of multiple dose administration of muraglitazar (BMS-298585), a novel PPARα/γdual agonist, in type 2 diabetic patients. 64th Annu Meet Sci Sess Am Diabetes Assoc (June 4, 2004 , Orlando) 2004: Abst 138-OR.
46. Lewin, A., Mihic, M., Modi, P. Addition of Oralin to metformin monotherapy to improve mealtime hyperglycemia and overall glycemic control in subjects with type 2 diabetes. 86th Annu Meet Endocr Soc (June 16, 2004, New Orleans) 2004: Abst OR8-1.
47. Berne, C. et al. Use of rosuvastatin versus atorvastatin in type 2 diabetes mellitus subjects: Results of the URANUS study. Atherosclerosis Suppl 2004, 5(1): Abst M.463.
48. Becker, M.A., Schumacher, H. Jr., Wortmann, R.L., Joseph-Dridge, N., Lademacher, C. A safety and efficacy clinical trial of a novel non-purine selective inhibitor of xanthine oxidase, febuxostat in subjects with gout. Ann Rheum Dis 2004, 63 (Suppl. 1): Abst OP0007.
49. Ahmed, S., Shwayhat, A.F., Aprill, B.S., Drake, A.J. III., Shakir, M.K.M. Ezetimibe (Zetia™) as a monotherapy for treating patients with hypercholesterolemia who are intolerant to other hypolipidemic drugs. 86th Annu Meet Endocr Soc (June 16, 2004, New Orleans) 2004: Abst P3-395.
50. Ballantyne, C., Blazing, M., King, T., Brady, W., Palmisano, J. Efficacy of coadministered ezetimibe + simvastatin versus atorvastatin alone in adults with hypercholesterolemia. Atherosclerosis Suppl 2004, 5(1): Abst M.456.
51. Denke, M.A., McBride, P., Pearson, T., Battisti, W., Brady, W.E., Palmisano, J. Ezetimibe added to statin therapy reduces LDL-C, TG and non-HDL-C and improves HDL-C in patients with diabetes and metabolic syndrome. 86th Annu Meet Endocr Soc (June 16, 2004, New Orleans) 2004: Abst OR53-4.
52. Bryson, A.M., Palmer, R.M.J., Kopelman, P. Efficacy and tolerabuity of ATL-962, a lipase inhibitor, in obese patients. Int J Obes 2004, 28 (Suppl. 1): Abst T5:O2-003.
53. Tardiff, B., Guler, H.-P., Heymsfield, S., Weinstein, S.; Recombinant human variant ciliary neurotrophic factor (rhvCNTF) induces weight loss via appetite reduction. Int J Obes 2004, 28 (Suppl. 1):Abst T5:P5b-036.
54. Roberts, W., Kassner, S., Bianco, D., Tardiff, B., Guler, H.-P., Weinstein, S. Safety and tolerability of recombinant human variant ciliary neurotrophic factor (rhvCNTF) for weight loss during a one-year clinical trial. Int J Obes 2004, 28 (Suppl. 1): Abst T5:P5b-035.
55. Abu-Lebdeh, H., Geohas, J., Brazg, R., Block, M., Noveck, R., Free, R., Jensen, M. The selective CB1-receptor antagonist rimonabant reduces body weight and waist circumference in obese subjects. Int J Obes 2004, 28 (Suppl. 1): Abst T5:O2-001.
56. Whelton, A., White, W.B., Kent, J.D., Verburg, K.M. Hypertension and edema rates in 6,717 patients for the new COX-2 inhibitor, valdecoxib versus the conventional, nonselective NSAIDs and placebo. Am J Hypertens 2003, 16 (5, Part 2): Abst P-446.
57. Curtis, S.P., Ng, J., Yu, Q.F., Shingo, S., Bergman, G., McCormick, C.L., Reicin, A.S. Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials. Clin Ther 2004, 26(1): 70.
58. Moreland, L.W. CTLA4Ig (Abatacept). Ann Rheum Dis 2004, 63 (Suppl. 1): Abst SP0075.
59. Durez, P. Hallegua, D., Nuamah, I., Vratsanos, G., Becker, J., Weisman, M. Abatacept (CTLA4Ig; BMS-188667) inhibits T-cell activation and the subsequent activation of inflammatory cell types, as demonstrated by sustained reductions in multiple inflammatory biomarkers. Ann Rheum Dis 2004, 63 (Suppl. 1): Abst THU0087.
60. Sibilia, J., Steinfeld, S., Nuamah, I., Aranda, R., Becker, J., Keystone, E. Efficacy of abatacept (CTLA4Ig; BMS-188667) in combination with methotrexate in the treatment of early and established rheumatoid arthritis. Ann Rheum Dis 2004, 63 (Suppl. 1): Abst OP0104.
61. Westhovens, R., Van Riel, P., Nuamah, I., Vratsanos, G., Becker, J., Dougados, M. Abatacept (CTLA4Ig; BMS-188667) plus methotrexate induces a rapid and sustained increase in remission rates in patients with active rheumatoid arthritis despite methotrexate treatment. Ann Rheum Dis 2004, 63 (Suppl. 1): Abst FRI0134.
62. Tugwell, P., Bombardier, C., Emery, P et al. Treatment with abatacept (CTLA4Ig; BMS-188667) in combination with methotrexate significantly improves physical function over 1 year in patients with active rheumatoid arthritis compared with methotrexate alone. Ann Rheum Dis 2004, 63 (Suppl. 1): Abst SAT0457.
63. Shergy, W., Sany, J., Nuamah, I., Aranda, R., Becker, J., Russell, A. Abatacept (CTLA4Ig; BMS-188667) treatment demonstrates rapid, consistent and sustained increases in ACR response rates over 1 year in patients with active rheumatoid arthritis. Ann Rheum Dis 2004, 63 (Suppl. 1): Abst FRI0119.
64. Townsend, R., Mikesell, G., et al., Nadler, S. Abatacept (CTLA4Ig: BMS-188667) significantly inhibits T-cell proliferation in vitro at clinically relevant concentrations. Ann Rheum Dis 2004, 63 (Suppl. 1): Abst THU0103.
65. Maini, R.N. Anti-IL6 receptor therapy: Rationale and early results in rheumatoid arthritis. Ann Rheum Dis 2004, 63 (Suppl. 1): Abst SP0074.
66. Wetter, D.A., Davis, M., Yiannias, J., Dahl, M. Intravenous immunoglobulin therapy: Effective in skin disease? A retrospective review of Mayo clinic experience. J Am Acad Dermatol 2004, 50 (3, Suppl.): Abst P34.
67. Hu, J.Z., Heilbrunn, K.R., Hurley, F.L., Joh, T., Linnik, M.D. Anti-dsDNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosiis: Results from 2 randomized controlled trials (RCTs) with LJP 394. Ann Rheum Dis 2004, 63 (Suppl. 1): Abst THU0364.
68. Cardiel, M.A., Tumlin, J.A., Bombardieri, S. et al. Summary of safety results from studies of LJP 394 in SLE patients. Ann Rheum Dis 2004, 63 (Suppl. 1): Abst THU0362.
69. Bias, P., Buchner, A. Potential for fewer cases of G1 tract microbleeding following treatment with the LOX/COX inhibitor, licofelone, compared with the conventional NSAID, naproxen. Ann Rheum Dis 2004, 63 (Suppl. 1): Abst FRI0409.
70. Bias, P., Schulz, U., Buchner, A. Licofelone, a 5-LOX, COX-1 and COX-2 inhibitor, is as effective as celecoxib over 12 weeks of treatment: OARSI/OMERACT-OARSI response criteria results. Ann Rheum Dis 2004, 63 (Suppl. 1): Abst FR10407.
71. Buchner, A., Schulz, U., Bias, P. Licofelone, a 5-LOX, COX-1 and COX-2 inhibitor, has excellent hepatic tolerability in patients with symptomatic OA of the knee. Ann Rheum Dis 2004, 63 (Suppl. 1): Abst FRI0408.
72. Schnitzer, T.J., Kivitz, A.J., Lipetz, R.S., Sanders, N., Hee, A. A phase II study of the efficacy and safety of AZD3582, a CINOD, in subjects with osteoarthritis of the knee. Ann Rheum Dis 2004, 63 (Suppl. 1): Abst OP0016.
73. Bogdahn, U., Hau, P., Brawanski, A. et al. Specific therapy for high-grade glioma by convection-enhanced delivery of the TGF-β2 specific antisense oligonucleotide AP 12009. Proc Am Soc Clin Oncol 2004, 23: Abst 1514.
74. Wadler, S., Mankower, D., Clairmont, C., Lambert, P., Fehn, K., Sznol, M. Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion. J Clin Oncol 2004, 22(9): 1553.
75. Rowinsky, E.K., Goldston, M.L., Mita, M.M. et al. Phase I, pharmacokinetic (PK), and phamacodynamic (PD) study of AP23573, an mTOR inhibitor, administered IV daily x 5 every other week in patients (pts) with refractory or advanced malignancies. Proc Am Soc Clin Oncol 2004, 23: Abst 3076.
76. Janisch, L., Berk, L.R., Knowles, H.L., Rivera, V.M., Bedrosian, C.L., Ratain, M.J., Desai, A.A. A phase I trial of a novel mTOR inhibitor AP23573 administered weekly (wkly) in patients (pts) with refractory or advanced malignancies: A pharmacokinetic (PK) and pharmacodynamic (PD) analysis. Proc Am Soc Clin Oncol 2004, 23: Abst 3150.
77. Dees, E.C., O'Neil, B., Humes, E., et al. Phase I clinical trial of the proteasome inhibitor bortezomib in combination with pegylated liposomal doxorubicin in patients with refractory solid tumors. Proc Am Soc Clin Oncol 2003, 22:Abst 868.
78. Buzzi, S., Rubboli, D., Buzzi, G., Buzzi, A.M., Morisi, C., Pironi, F. CRM197: Effects of intravenous administration to advanced cancer patients. Proc Am Assoc Cancer Res 2004, 45: Abst 3803.
79. Kurman, M.R. et al. IRX-2 protocol improves outcome in head and neck cancer. Proc Am Soc Clin Oncol 2003, 22: Abst 755.
80. Holen, K.D., Syed, S., Hannah, A.L. et al. Phase I study using continuous intravenous (CI) KOS-862 (epothilone D) in patients with solid tumors. Proc Am Soc Clin Oncol 2004, 23: Abst 2024.
81. Wilding, G. et al. Phase I trial of the polyamine analog N1,N14-diethylhomospermine (DEHSPM) in patients with advanced solid tumors. Invest New Drugs 2004, 22(2): 131.
82. Jonker, D.J., Avruch, L., Stewart, D.J. et al. A phase I safety and PK study of the novel vascular targeting agent (VTA), Exherin, in patients with refractory solid tumors stratified according to N-cadherin expression. Proc Am Soc Clin Oncol 2004, 23: Abst 3078.
83. Crombet, T., Osorio, M., Cruz, T. et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004, 22(9): 1646.
84. Thambi, P.M., Egderly, M., Agrawal, M., Kotz, H., Bates, S., Bakke, S., Quigley, S., Fojo, T. A phase I clinical trial of BMS-247550 (NSC 71028), an epothilone B derivative, given daily for 3 days on a 21 day cycle in patients with refractory neoplasms. Proc Am Soc Clin Oncol 2003, 22: Abst 540.
85. Kim, E.S. et al. Khuri, F.R., Glisson, B.S.; Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin Cancer Res 2004, 10(9): 2968.
86. MacKenzie, M.J., Hirte, H.W., Siu, L.L., Gelmon, K., Ptaszynski, M., Fisher, B., Eisenhauer, E. A phase I study of OS1-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers. Ann Oncol 2004, 15(4): 665.
87. Springett, G.M., Takimoto, C., McNamara, M. et al. Phase I study of CT-2106 (polyglutamate camptothecin) in patients with advanced malignancies. Proc Am Soc Clin Oncol 2004, 23: Abst 3127.
88. Tanaka, K., Kambayashi, Y., Yoshioka, T. Antitumor effect of MMP inhibitors. Jpn J Urol 2004, 95 (2): Abst CP8-7.
89. Schoffski, P., Thate, B., Beutel, G. et al. Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer. Ann Oncol 2004, 15(4): 671.
90. Nemunaitis, J.J., Haltom, E., Cunningham, C.C. et al. A phase I trial of PT-100 in patients receiving myelosuppressive chemotherapy. Proc Am Soc Clin Oncol 2004, 23: Abst 2572.
91. Quinn, D.I., Gorospe, G., Lenz, H.J., Tulpule, A., Levine, A.M. Phase I trial of anti-sense oligonucleotide vascular endothelial growth factor (VEGF-AS. Veglin) in patients with relapsed and refractory malignancies. Proc Am Soc Clin Oncol 2004, 23: Abst 3008.
92. Grossman, H.B., Gomella, L.G., Fradet, Y. et al. The use of Hexvix and fluorescence cystoscopy as an adjunct in the diagnosis of stage Ta/T1 urothelial cancer in the urinary bladder. J Urol 2004, 171 (4, Suppl.): Abst 263.
93. Gomella, L.G., Grossman, H.B., Presti, J.C. Jr. et al. The use of Hexvix and fluorescence cystoscopy as an adjunct in the diagnosis of stage Ta/T1 urothelial cancer in the urinary bladder. J Urol 2004, 171 (4. Suppl.): Abst 264.
94. Durek, C., Wagner, S., Zeijlemaker, B. et al. The impact of Hexvix based fluorescence cystoscopy in treatment decisions of bladder cancer - Results of a prospective phase III multicenter study. J Urol 2004, 171 (4, Suppl.): Abst 278.
95. Armstrong, J.L., Ragupathi, G., Powell, S., Norton, L., Houghton, A.N., Livingston, P.O., Gilewski, T. Preliminary data of vaccination of high risk breast cancer (BC) patients (pts) with a heptavalent antigen: Keyhole limpet hemocyanin (KLH) conjugate plus the immunologic adjuvant QS-21. Proc Am Soc Clin Oncol 2003, 22: Abst 675.
96. Peethambaram, P. et al. Antigen presenting cell based immunotherapy targeting HER2/Neu positive solid tumors: Results of a phase I study of APC8024. Proc Am Soc Clin Oncol 2004, 23: Abst 2528.
97. Wadler, S., Levy, D., Frederickson, H.L. et al. A phase II trial of interleukin-12 in patients with advanced cervical cancer: Clinical and immunologic correlates Eastern Cooperative Oncology Group study E1E96. Gynecol Oncol 2004, 92(3): 957.
98. Hurwitz, H., Fehrenbacher, L., Fyfe, G.A. et al. Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of met astatic colorectal cancer results in survival benefit in all pre-specified patient sub-groups. Proc Am Soc Clin Oncol 2004, 23: Abst 3617.
99. Schulz, J., McCleod, M., Kabbinavar, F.F. et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) to prolong progression-free survival in first-line colorectal cancer (CRC) in subjects who are not suitable candidates for first-line CPT-II. Proc Am Soc Clin Oncol 2004, 23: Abst 3516.
100. Ishioka, G.Y., Disis, M.L., Morse, M.A. et al. A phase I trial, of a multi-epitope cancer vaccine (EP-2101) in non-small cell lung (NSCLC) and colon cancer patients. Proc Am Soc Clin Oncol 2004, 23: Abst 2525.
101. Torzilli, G., Del Fabbro, D., Gambetti, A., Leoni, P., Olivari, N. Contrast-enhanced intraoperative ultrasonography during surgery for liver lesion resection. J Hepatol 2004, 40 (Suppl. 1): Abst 272.
102. Jankilevich, G., Chacon, M., Barugel, M. et al. Gastrointestinal stromal tumors (GISTs) in Argentina in the era of imatinib: Diagnostic problems and treatment results. Proc Am Soc Clin Oncol 2003, 22: Abst 1444.
103. Wood, C.G. et al. A multicenter randomized study of adjuvant heat-shock protein peptide-complex 96 (HSPPC-96) vaccine in patients with high-risk of recurrence after nephrectomy for renal cell carcinoma (RCC) - a preliminary report. Proc Am Soc Clin Oncol 2004, 23: Abst 2618.
104. Sosman, J.A., Spigel, D.R., Schwert, R.C., Carrell, D.L., Hubbard, F., Greco, F.A., Hainsworth, J.D. Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC). Proc Am Soc Clin Oncol 2004, 23: Abst 4502.
105. Bleumer, I., Knuth, A., Oostrwijk, E. et al. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 2004, 90(5): 985.
106. Al-Atrash, G. et al. Toxicity and immunologic effects of subcutaneously (SC) administered IL-12 and IFN-α2b in patients (pts) with metastatic renal cell carcinoma (RCC) or malignant melanoma (MM). Proc Am Soc Clin Oncol 2003, 22: Abst 705.
107. Aamdal, S., Fernberg, L., Engelhart, R., Fodstad, O., Forsberg, G. Tumor targeted superantigen therapy in advanced non-small cell lung cancer: A phase I dose escalation study of ABR-214936, anatumomab mafenatox. Proc Am Soc Clin Oncol 2003, 22: Abst 718.
108. Blumenschein, G.R., Henderson, T., Sandler, A.B. et al. Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer. Proc Am Soc Clin Oncol 2004, 23: Abst 2000.
109. Nakagawa, K., Kudoh, S., Matsui, K. et al. A phase I dose-finding study of pemetrexed supplemented with folic acid (FA) and vitamin B12 in Japanese patients with solid tumors. Proc Am Soc Clin Oncol 2003, 22: Abst 632.
110. Rose, V. et al. Randomized phase II trial of weekly squalamine, carboplatin, and paclitaxel as first line therapy for advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2004, 23: Abst 7109.
111. Hawkins, R. et al. A multiple ascending dose, open-label, phase IIa study evaluating the safety and tolerability of PCK3145 administered intravenously in patients with metastatic hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 2004, 23: Abst 4636.
112. Daigneault, L. et al. Evaluation of biological activity of PCK3145 in metastatic hormone resistant prostatic cancer (HRPC) using serum markers. Proc Am Soc Clin Oncol 2004, 23: Abst 4692.
113. Seiden, M.V., Muggia, F., Astrow, A. et al. A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer. Gynecol Oncol 2004, 93 (1): 229.
114. Rutherford, T., O'Malley, D., Makkenchery, A., Baker, L., Azodi, M., Schwartz, P., Mor, G. Phenoxodiol phase Ib/II study in patients with recurrent ovarian cancer that are resistant to equal to or more than second line chemotherapy. Proc Am Assoc Cancer Res 2004, 45: Abst 4457.
115. Seiden, M., Butler, M., Hodi, F.S. et al. Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody blockade in patients previously vaccinated with irradiated, autologous tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor (GM-CSF). Proc Am Soc Clin Oncol 2004, 23: Abst 2536.
116. Kindler, H.L., Friberg, G., Stadier, W.M. et al. Bevacizumab plus gemcitabine is an active combination in patients with advanced pancreatic cancer: Interim results of an ongoing phase II trial from the University of Chicago Phase II Consortium. Gastrointest Cancers Symp (Jan 22, 2004, San Francisco) 2004: Abst 86.
117. Friberg, G., Stadler, W.M., Kindler, H.L. et al. Bevacizumab (B) plus gemcitabine (G) in patients (pts) with advanced pancreatic cancer (PC): Updated results of a multi-center phase II trial. Proc Am Soc Clin Oncol 2004, 23: Abst 4009.
118. Rini, B., Kavanaugh, B., Small, E., Fong, L. CTLA-4 blockade-based immunotherapy for prostate cancer. Proc Am Soc Clin Oncol 2004, 23: Abst 2590.
119. Beijnen, J.H., Rademaker-Lakhai, J.M., Horenblas, S. et al. Phase I and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer. Proc Am Soc Clin Oncol 2004, 23: Abst 2076.
120. Apisarnthanarax, N., Ke, M.S., Szabo, S.K. et al. Phase I clinical trial of O6beniylguanine and topical BCNU in the treatment of cutaneous T-cell lymphoma. Proc Am Soc Clin Oncol 2003, 22: Abst 2295.
121. Henwood, M., Gilliam, A.D., Watson, S.A. et al. A phase II study of G17DT in gastric carcinoma. Eur J Surg Oncol 2004, 30(5): 536.
122. Giantonio, B.J., Levy, D., O'Dwyer, P.J., Meropol, N.J., Catalano, P.J., Benson, A.B. Bevacizumab (anti-VEGF) plus IFL (irinotecan, fluorouracil, leucovorin) as front-line therapy for advanced colorectal cancer (advCRC): Updated results from the Eastern Cooperative Oncology Group (ECOG) study E2200. Gastrointest Cancers Symp (Jan 22, 2004, San Francisco) 2004: Abst 289.
123. Giles, F., Thomas, D., Garcia-Manero, G. et al. A phase I and pharmacokinetic study of VNP4010IM, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia. Clin Cancer Res 2004, 10(9): 2908.
124. Carabasi, M.A., Bartlett, N.L., Younes, A. et al. Pharmacokinetics, safety, and tolerability of SGN-30, a chimeric monoclonal antibody (mAb), administered as a single dose to patients with CD30+ hematologic malignancies. Proc Am Soc Clin Oncol 2003, 22: Abst 722.
125. Parmiani, G. Phase II study of HSPPC-96 in combination with GM-CSF and IFN-α in stage IV malignant melanoma. Proc Am Soc Clin Oncol 2004, 23: Abst 7510.
126. Weber, J., Powderly, J., Hersh, E.M. et al. A phase II, randomized multi-center study of MDX-010 alone or in combination with dacarbazine (DTIC) in stage IV metastatic malignant melanoma. Proc Am Soc Clin Oncol 2004, 23: Abst 7511.
127. Bensinger, W. et al. 166Ho-DOTMP skeletal targeted radiotherapy with melphalan and autologous stem cell support for multiple myeloma. Proc Am Soc Clin Oncol 2004, 23: Abst 6656.
128. Fox, M., Calandra, G., Tricot, G., Fassas, A. Successful mobilization of peripheral blood stem cells (PBSCs) with AMD3100 in patients failing to collect with hematopoietic growth factors (HGF) and/or chemotherapy. Proc Am Soc Clin Oncol 2004, 23: Abst 6643.
129. Kurzrock, R., Albitar, M., Cortes, J.E., et al. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol 2004, 22(7): 1287.
130. Mulchahey, J., Zemlan, F., Mayleben, D., Scharf, M., Rosenberg, R., Lankford, A. Multicenter study of the safety and efficacy of the melatonin agonist LY156735 in primary insomnia. 86th Annu Meet Endocr Soc (June 16, 2004, New Orleans) 2004: Abst P2-223.
131. Diener, H.-C. et al. Efficacy and tolerability of eletriptan vs sumatriptan 100 mg for the acute treatment of migraine. 7th Congr Eur Fed Neurol Soc (Aug 30, 2003, Helsinki) 2003: Abst 276.
132. Krusz, J.C. Frovatriptan for migraine pre-emption. 7th Congr Eur Fed Neurol Soc (Aug 30, 2003, Helsinki) 2003: Abst 329.
133. Sonesson, C., Waters, N., Waters, S., Carlsson, A., Tedroff, J. A pilot study of the novel dopamine stabiliser ACR16 in advanced Parkinson's disease. Mov Disord 2004, 19 (Suppl. 9): Abst P565.
134. LeWitt, PA. "Off" time reduction from adjunctive use of istradefylline (KW-6002) in levodopa-treated patients with advanced Parkinson's disease. Mov Disord 2004, 19 (Suppl. 9): Abst P624.
135. Stacy, M.A. Istradefylline (KW-6002) as adjunctive therapy in patients with advanced Parkinson's disease: A positive safety profile with supporting efficacy. Mov Disord 2004, 19 (Suppl. 9): Abst P605.
136. Silver, D., Guarnieri, M., Hubble, J., Rabinowicz, A., Koller, W. A prospective evaluation of the tolerability and safety of Stalevo™ (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. Mov Disord 2004, 19 (Suppl. 9): Abst P577.
137. Oertel, W. Stalevo (levodopa/carbidopa/entacapone) provides improved symptom control in fluctuating Parkinson's disease patients comparable to levodopa/DDCI given in combination with entacapone. Mov Disord 2004, 19 (Suppl. 9): Abst P736.
138. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004, 61(4): 561.
139. Boroojerdi, B., Poole, K.H., Sommerville, K.W., Güldenpfennig, W.M. A dose escalation trial of rotigotine CDS in patients with early-stage idiopathic Parkinson's disease. Mov Disord 2004, 19 (Suppl. 9): Abst P506.
140. Wendt, J., Nausieda, P.L., Boroojerdi, B., Poole, K.H., Sommerville, K.W., Watts, R.L. Efficacy, safety, and tolerability of the rotigotine transdermal patch in patients with early-stage, idiopathic Parkinson's disease: A multicenter, multinational, randomized, double-blind, placebo-controlled trial. Mov Disord 2004, 19 (Suppl. 9): Abst P737.
141. Vacca, L., Grassini, P., Battaglia, G., Altibrandi, M., Ruggieri, S.A., Stocchi, F. Safinamide add-on to levodopa and dopamine agonist treatment in Parkinson disease: An open, escalating dose study. Mov Disord 2004, 19 (Suppl. 9): Abst P631.
142. Sangal, R.B. et al. Effects of atomoxetine and methylphenidate on sleep in children with ADHD. Sleep 2004, 27 (Suppl.): Abst 197.
143. Wernicke, J.F., Adler, L., Spencer, T. et al. Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: A prospective, placebo-controlled assessment. J Clin Psychopharmacol 2004, 24(1): 30.
144. Kramer, M.S., Winokur, A., Kelsey, J. et al. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 2004, 29(2): 385.
145. Ebrecht, M. et al. Aripiprazole versus perphenazine in treatment-resistant schizophrenia. 12th Assoc Eur Psychiatr Congr (April 14, 2004, Geneva) 2004: Abst.
146. Paul, M.A., Gray, G., MacLellan, M., Pigeau, R.A. Sleep-inducing pharmaceuticals: A comparison of melatonin, zaleplon, zopiclone, and temazepam. Aviat Space Environ Med 2004, 75(6): 512.
147. Schols, A.M.W.J., Maltais, F., O'Donnell, D.E. et al. Anabolic effects and safety assessment of TH9507, a growth hormone releasing factor (GRF) analog in patients with COPD-associated wasting. 86th Annu Meet Endocr Soc (June 16, 2004, New Orleans) 2004: Abst P1-421.
148. Anstey, A. V., Bibby, A. A pooled analysis of studies with a new calcipotriene/betamethasone two-compound product in psoriasis vulgaris. J Am Acad Dermatol 2004, 50 (3, Suppl.): Abst P1.
149. Griffiths, C., Dubertret, L., Gottlieb, A. Treatment with oral pimecrolimus significantly improves psoriasis with a clear dose-response effect. 64th Annu Meet Soc Invest Dermatol (April 30, 2003, Miami Beach) 2003: Abst 0391.
150. Sivin, I., Croxatto, H., Bahamondes, L. et al. Two-year performance of a Nestorone®-releasing contraceptive implant: A three-center study of 300 women. Contraception 2004, 69(2): 137.
151. Viscusi, E. et al. In-hospital resource use to manage pain after single presurgery dose of IV parecoxib sodium, a novel prenteral COX-2 inhibitor, for pain associated with laparoscopic cholecystectomy surgery (LCS). 4th Congr Eur Fed IASP Chapters (Sept 2, 2003, Prague) 2003: Abst 622.W.
152. Colwell, C.W. Jr., Berkowitz, S.D., Comp, P.C. et al. Ximelagatran provides greater prevention of VTE after total knee replacement than warfarin. 71st Annu Meet Am Acad Orthop Surg (March 10, 2004, San Francisco) 2004: Abst 060.
153. Haverich, A., Tuzcu, E.M., Vigano, M. et al. Everolimus in de novo cardiac transplant recipients: 24-month follow-up. J Heart Lung Transplant 2003, 22 (1, Suppl.): Abst 207.
154. Stone, N., Dunaway, S., Flexner, C. et al. Biologic activity of an orally bioavailable CXCR4 antagonist in human subjects. 5th Int Workshop Clin Pharmacol HIV Ther (April 1, 2004, Rome) 2004: Abst 36.
155. Swaminathan, A. et al. Pharmacokinetics of single doses of the novel PPARα/γ dual agonist muraglitaiar (BMS-298585) in healthy human subjects. 64th Annu Meet Sci Sess Am Diabetes Assoc (June 4, 2004, Orlando) 2004: Abst 618-P.
156. Lamarre-Cliche, M., Bissery, A., Labatide-Alanor, A., Menard, J., Michel, A. Pharmacodynamic effects of single oral doses of omapatrilat (40 and 80 mg) and fosinopril (20 mg) during salt depletion and salt repletion in normotensive subjects. Am J Hypertens 2003, 16 (5, Part 2): Abst P-228.
157. Park, A., Sileno, A., Brandt, G., Quay, S., Bloom, S. Intranasal administration of peptide YY3-36: A phase I dose ranging and safety study in healthy human subjects. 86th Annu Meet Endocr Soc (June 16, 2004, New Orleans) 2004: Abst P1-346.
158. Allas, S., Lussier, B., Chapdelaine, A., Cadeau, M., Abribat, T., Vachon, L. Endocrine and metabolic effects of TH9507, a growth-hormone releasing factor (CRF) analog, in elderly male and female subjects. 86th Annu Meet Endocr Soc (June 16, 2004, New Orleans) 2004: Abst P1-414.